Standard reference images are important to standardize and benchmark different staining and imaging protocols. JEDI is a multi-disciplinary taskforce with more than 30 members across the world, working closely with the Society of Immunotherapy for Cancer (SITC) and World Immunotherapy Council (WIC) to help the standardization and translation of multiplex IHC/IF technologies for clinical research and cancer immunotherapy application.
A study based on simultaneous detection and quantification of three different programmed death-ligand 1 (PD-L1) antibodies found moderate-to-strong correlations between their staining levels in conventional immunohistochemistry (IHC) and multiplex immunohistochemistry/ immunofluorescence (mIHC/IF).
- ImmunoAtlas Report for the study (ATLA-201129-1)
A study showed that quantifications of CD38+ cells and CD38+CD68+ macrophages can more accurately predict immune-checkpoint-blockade responsiveness than quantifications based on programmed death-ligand 1 (PD-L1) or CD8+ T cells only.
- ImmunoAtlas Report for the study (ATLA-201126-1)
A new study performed whole-slide multiplexed immunohistochemistry and immunofluorescence (mIHC/IF) and hematoxylin and eosin (H&E) staining and imaging on the same human tonsil section. This is a promising method to simultaneously and spatially quantify overall tissue morphology and various molecular phenotypes of cancer and immune cells in the tumor microenvironments.